TME Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy now. Even though the chart is still in a bearish moving-average structure, TME is trading right on a key pivot/support zone (~16.75) with strong fundamental momentum (2025/Q3 revenue +20.6% YoY, EPS +38% YoY) and a broadly bullish sell-side setup (most firms still Buy/Overweight with targets far above $16.78). Options positioning is also constructive (puts below calls on both OI and volume). For an impatient buyer, the current level near support offers a favorable entry versus upside to the next resistance band (17.50–17.96) and multi-month sell-side targets (21–29).
Price/Trend: Down on the day (regular -2.27%; post-market $16.78) and the trend is still technically bearish because SMA_200 > SMA_20 > SMA_5 (rallies may face supply until this stack improves).
Momentum: MACD histogram is positive (0.0884) but contracting, implying upside momentum exists but is fading—more consistent with a basing attempt than a fresh breakout.
RSI: RSI_6 ~44.9 (neutral-to-slightly-weak), not oversold—so a bounce is possible, but not a high-certainty mean-reversion setup.
Key levels: Pivot ~16.752 (price is sitting on it). Immediate support S1 ~16.003 (failure below here increases downside risk toward S2 ~15.541). Resistance levels to reclaim are R1 ~17.501 then R2 ~17.963.
Pattern-based short-horizon stats: Similar-pattern model suggests modest next-day upside (+0.9%), slight 1-week drift (-1.05%), and a more favorable 1-month bias (+4.57%).
Intellectia Proprietary Trading Signals
Fundamentals remain strong: 2025/Q3 delivered robust growth (revenue +20.64% YoY; net income +36.01% YoY; EPS +38% YoY) and slightly improved gross margin (+2.04% YoY), supporting a higher multiple if growth durability holds.
Potential event upside: Approval/progress on the Ximalaya deal could unlock a sentiment/valuation lift (noted by Morgan Stanley as a timing factor).
Sell-side skew remains favorable: Multiple Buy/Overweight ratings with targets well above the current price suggest room for re-rating if execution remains solid.
Technical positioning: Current price is sitting on a defined pivot/support area (~16.75), which can attract dip buyers.
implies the broader trend is still down/weak and rebounds may be sold.
Latest quarter: 2025/Q3. Growth: Revenue rose to 8,463,000,000 (+20.64% YoY). Net income increased to 2,153,000,000 (+36.01% YoY). EPS grew to 0.69 (+38.00% YoY). Margins: Gross margin improved to 43.51% (+2.04% YoY), showing operating quality has not deteriorated in the reported quarter. Takeaway: The quarter shows accelerating earnings vs revenue (operating leverage), which supports a bullish medium-term thesis even if the chart is still repairing.
Recent trend: Price targets have been trimmed by multiple firms (Morgan Stanley 27.50→25; BofA 25→21; Benchmark 28→25), mainly on catalyst timing (Ximalaya approval) and potential margin pressure/mix shift. However, overall ratings skew positive: Morgan Stanley Overweight, Benchmark Buy, Barclays Overweight, Citi Buy; only BofA is Neutral. Wall Street pros: Strong Q3 performance, belief that the growth story is intact, and several firms viewed prior post-earnings selloffs as a buying opportunity. Wall Street cons: Near-term catalyst visibility and concerns about margin trajectory and competitive noise. Influential/political trading: No recent congress trading data available; no politician/influential figure transactions were provided. Hedge funds and insiders are reported as Neutral with no significant recent trends.
